In summary, these results point to the potential involvement of SREBF-1 as a new factor for acquired therapy resistance and underline the hypothesis that elevated SREBF-1 expression plays an essential role in advanced PCa.26 Here, SREBF1 is linked to posterior cortical atrophy.